Business Wire

METI will hold GGX x TCFD Summit

27.9.2023 15:35:00 EEST | Business Wire | Press release

Share

From 10:00 on October 2 (Mon.), the Ministry of Economy, Trade and Industry (METI) will hold the Global Green Transformation (GGX) Conference and the TCFD Summit, which until now have attracted participation from a wide range of sectors including global industry, finance, governments, regulators, and international organizations, will be held jointly. In order to further develop discussions on transition finance, avoided emissions, industry decarbonization, and other topics related to how business and finance contribute to decarbonization, the event will promote mutual cooperation between the government, business, and financial sectors, and hold discussions to lead the international rule-making process to achieve both emission reductions and economic growth.

  • Outline of Global Green Transformation (GGX) Conference and the TCFD Summit

Date: October 2nd, 2023 10:00-17:00 (JST)
Organizer: Ministry of Economy, Trade and Industry (METI)
Co-organizer: TCFD Consortium, The World Business Council for Sustainable Development (WBCSD)
Format: Hybrid (On-Site and On-Line)
Web Site: https://tcfd-summit.go.jp/indexEn.html

  • Online Registration

Online Registration Site: https://jcs.eventsair.com/ggxtcfd2023/attendeereg/Site/Register
*Registration deadline: Oct 1st (Sun.) (JST, GMT+9:00)

  • Program
  • Opening Remarks
    HATAKEYAMA Yojiro (Director-General, Industrial Science, Technology and Environment Policy Bureau, Ministry of Economy, Trade and Industry)
    TOKURA Masakazu (Chairman, Keidanren (Japan Business Federation))
    KATO Masahiko (Chairperson, Japanese Bankers Association)
    David Atkin (CEO, Principles for Responsible Investment (PRI))
  • Keynote Speech 1
    Gianluigi Benedetti (Ambassador, Embassy of Italy in Tokyo)
  • Panel Discussion 1 “Towards Net-Zero Society ~Industrial Decarbonisation~”
    What efforts are needed towards creating a "Green Market" to accelerate industrial decarbonization, focusing on the creation of demand?
    [Moderator]
    Peter Bakker (President and CEO, World Business Council for Sustainable Development (WBCSD))
    [Panelist]
    Nancy Gillis (Program Head, First Movers Coalition, World Economic Forum)
    Rana Ghoneim (Chief, Energy Systems and Industrial Decarbonization Unit, United Nations Industrial Development Organization)
    TEZUKA Hiroyuki (Fellow, Executive, JFE Steel Corporation)
    MITA Noriyuki (Vice President, Sustainability Department, Mitsubishi Chemical Group Corporation *After October 1st)
    KOBAYASHI Izuru (Deputy Director-General for Environmental Affairs, Ministry of Economy, Trade and Industry)
  • Panel Discussion 2 “Solution Provider and Avoided Emissions”
    Companies are increasingly expected to provide solutions to social challenges. What is the potential of the idea of "avoided emissions" to evaluate a company's contribution to decarbonization of the society as a whole by providing solutions?
    [Moderator]
    HAYASHI Reiko (Director and Deputy President, BofA Securities Japan Co., Ltd.)
    [Panelist]
    Jason Mortimer (Head of Sustainable Investment - Fixed Income, Investment Department - Global Solutions, Nomura Asset Management)
    UEHARA Hirotoshi (Executive Officer, Quality & Environment, CS, Panasonic Operational Excellence Co., Ltd.)
    HIRUTA Takako (Country Leader, CS&Q, Schneider Electric Japan, Inc)
  • Keynote Speech 3
    Emmanuel Faber (Chair, ISSB)
    MIYAZONO Masataka (President, Government Pension Investment Fund)
    MIZUNO Hiromichi (Founder And CEO, Good Steward Partners, LLC)
  • Panel Discussion 3 “Future of Climate-Related Financial Disclosures”
    As climate-related financial disclosures rapidly expand, what efforts are needed going forward? How can disclosure promote transition finance?
    [Moderator]
    NAGAMURA Masaaki (Fellow, International Initiatives, Tokio Marine Holdings, Inc.)
    [Panelist]
    Alex Michie (Head of Secretariat, GFANZ)
    IKEDA Satoshi (Chief Sustainable Finance Officer, Strategy Development And Management Bureau, Financial Services Agency)
    ISHIKAWA Tomohiro (Chief Regulatory Engagement Officer, Corporate Planning Division, Mitsubishi UFJ Financial Group (MUFG))
    KITAGAWA Keiko (General Manager, Sustainability Promotion Unit, Global Investor Relations Group, Finance Strategy and Planning Division, JERA Co., Inc.)
  • Keynote Speech 4
    Mary Schapiro (Head, The TCFD Secretariat)
    ITO Kunio (Chair, The TCFD Consortium)
  • Panel Discussion 4 “Further Promotion of Transition Finance”
    As the understanding of the importance of transition finance grows globally, what efforts are needed to further promote investments toward decarbonization of corporates and the private financing towards them?
    [Moderator]
    KIHARA Shinichi (Director General for International Policy on Carbon Neutrality, Ministry of Economy, Trade and Industry)
    [Panelist]
    Nicholas Pfaff (Deputy Chief Executive, Head of Sustainable Finance, International Capital Market Association)
    Sean Kidney (CEO, Climate Bonds Initiative)
    Eila Kreivi (Director, Chief Sustainable Finance Advisor, Secretariat General, European Investment Bank)
    KUBOTA Nobuhiko (Managing Executive Officer, General Manager of Technology & Intelligence Integration, IHI Corporation)
  • Closing Remarks
    Peter Bakker (President and CEO, World Business Council for Sustainable Development (WBCSD))

*The above programs and speakers may be subject to change at the discretion of the organizer.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contact information for inquiries
GGX x TCFD Summit 2023 Registration Desk
E-mail: ggxtcfd2023-reg@convention.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release

The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn

Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release

Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is

Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release

Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net

Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release

Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un

Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release

Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye